EVERSANA Global Services Expansion Includes New COO

Sy Pretorius has been named the global commercialization company’s new Chief Operating Officer and President, Outsourced Solutions. Pretorius joins EVERSANA from Parexel where he served as President, Clinical Development and Chief Medical Officer. With over 25 years of experience in clinical development and commercial operations, he will now be responsible for driving operational excellence across the company’s growing outsourced operations including Channel Management, Compliance Services, Field Deployment Solutions, and Patient Services, as well as critical infrastructure teams including Information Technology and Business Transformation.

Pretorius joins EVERSANA as it moves to expand its global commercialization services, committing to transforming the healthcare sector. Jim Lang, CEO, EVERSANA speaks of Sy Pretorius: “His deep experiences and knowledge of clinical development, coupled with an unprecedented ability to lead large organizations, will shepherd our growth. Sy continues to be on the leading edge of innovation—first within CROs and now as we lead commercialization service excellence.”

Anagenex Taps GSK Executive

Anagenex, a leading drug discovery company that pairs large-scale data generation with machine learning to discover the next generation of small molecule medicines, brought on Ryan Kruger, PhD, as its new Chief Scientific Officer. Dr. Kruger served most recently as Vice President and Head of Biology at Foghorn Therapeutics and was Head of the Cancer Epigenetics Research Unit in the Oncology R&D division at GlaxoSmithKline for a majority of his 18-year career.

“The most important thing for a technology-first drug discovery company is to know where to aim the platform for maximum impact,” said Nicolas Tilmans, CEO of Anagenex. “Ryan has a truly exceptional understanding of the biochemistry behind disease, and his leadership will ensure that our efforts will connect to patients in need. I’m overjoyed to have him join us on this journey.”


Innovative marketing and analytics expert Rebecca Visconti has joined the agency as Vice President of Marketing Intelligence. She is charged with leading all aspects of the agency’s marketing intelligence services, leading a team of specialists who provide data, analysis, insights, multi-touch attribution models, predictive data intelligence, and success metrics for enhancing client and agency decision-making and optimizing the impact of client marketing campaigns.

Aclaris Therapeutics

The clinical-stage biotech focused on developing novel drug candidates for immuno-inflammatory diseases, announced key leadership changes, including Douglas Manion, MD as the new Chief Executive Officer. Dr. Manion originally joined Aclaris as President and Chief Operating Officer in August 2022, bringing over 25 years of pharmaceutical industry experience in both large and small companies.

Atriva Therapeutics

Christian Pangratz has been named the Chief Executive Officer of Atriva Therapeutics GmbH, guiding the company pioneering the development of host-targeting antiviral therapies. Pangratz has a track record in leading innovative biotech companies and will focus on the company’s successful commercial development of lead drug candidate, zapnometinib.

Cogent Biosciences

Rachael Easton, MD, PhD has been appointed to the position of Vice President, Head of Clinical Development of Cogent Biosciences. Prior to joining Cogent, Dr. Easton was Group Senior Medical Director, Oncology Clinical Development at GSK. Her background and knowledge will be trusted to advance programs bringing important therapies to patients with genetically defined diseases.

FINN Partners

The global marketing firm promoted Jessica A. Lise to Partner, New York Health, recognizing her contributions to providing industry-leading client service and growing FINN’s New York Health group. Lise designs high-level communications strategies and tactically executes against them to consistently exceed client expectations, and will now do so on the Global Health Practice Leadership Team.

Freedom Biosciences

David Hough, MD departed Janssen as its psychiatric lead in 2020 and will now lead clinical development as Chief Medical Officer of Freedom Biosciences, a company focused on developing ketamine and psychedelic-based therapeutics for psychiatric disorders. At both Janssen and Johnson & Johnson, Dr. Hough headed schizophrenia disease areas and led esketamine compound development.

HpVac SA

The company developing therapies against allergic and inflammatory diseases brought on Joana Vitte, MD, PhD, Habil as its new Chief Scientific Officer. Dr. Vitte is an expert in allergy diagnostics and clinical research. She will be a key component in furthering the company’s clinical development as it further develops microbiome-based immune modulation methods.

Johnson & Johnson

The pharma giant has given current CEO Joaquin Duato the additional role of Chairman of the Board. Duato has been with the company for 30 years in various roles and has served as CEO since January 2022, displaying a constant ability to effectively lead, collaborate, and create value for all stakeholders.


David Jiménez has been named General Manager, United States of Moderna where he will be responsible for commercial efforts in the U.S. Jiménez spent two decades at Johnson & Johnson in a variety of leadership roles and, in his most recent role, served as President for Janssen Immunology. His expertise will help the company transition to a commercial vaccine market in the U.S. and to advance new candidates in coming years.

Precision BioSciences

The clinical-stage gene editing company announced that Dr. Raymond Schinazi is stepping down from the Board of Directors, but will remain on the Scientific Advisory Board. There he will continue to lend his expertise in antiviral drug discovery and development of the company’s CAR T and in vivo gene editing pipeline. He will help guide Precision in developing potentially transformative treatment and curative options for high unmet patient needs.

Rewind Therapeutics

The drug developer focused on demyelination-associated diseases appointed Stephen Burbidge, PhD to the management team as Head of Research and Discovery. His 20 years of drug discovery and development expertise will help move Rewind’s pipeline towards clinical development and eventually providing novel therapeutics to patients suffering from demyelination-related diseases like multiple sclerosis.

STADA Arzneimittel AG

Previous Head, Latin America, at Sanofi Consumer Healthcare, Stéphane Jacqmin has joined STADA, the company specializing in generics, specialty pharma, and non-prescription consumer healthcare products, as Head of Emerging Markets. Jacqmin brings extensive leadership and management experience in consumer healthcare and fast-moving consumer goods.


You May Also Like


Clients using eSight, an invention by Gentex, to increase 20/20 vision. Gentex Releases New ...

PM360 Greatest Creators Showcase 2022 Selection AbelsonTaylor

AbelsonTaylor Sunovion Pharmaceuticals Latuda “Real Expressions” Campaign The “Real Expressions” campaign features art inspired ...

Off-Label or Off Course?

Drug-makers are mostly prohibited from disseminating information on unapproved uses of approved products. Sometimes, ...